24th Feb 2009 11:10
Notification of Transactions of Directors and
Persons Discharging Managerial Responsibility
Vesting of awards made under GlaxoSmithKline's share plans in 2006
This notification, prepared in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a), sets out the vesting of share options made in 2006, under the GlaxoSmithKline Share Option Plan.
The three-year performance period for the GlaxoSmithKline Share Option Plan awards made to appointed CET members in 2006, at an option price of £14.68 (or US$51.02 in the case of ADSs), which commenced on 1 January 2006, came to an end on 31 December 2008. The performance conditions for this grant were not fully met for awards made to the then Executive Directors and CET members who are all persons discharging managerial responsibility. The Remuneration Committee of the Board of GlaxoSmithKline therefore confirmed that 50.7% of the original grant was exercisable.
|
Number of options over Shares/ADSs exercisable |
||
|
Shares |
ADSs |
|
|
Mr A P Witty* |
89,993 |
|
|
Mr J S Heslop* |
117,117 |
|
|
Mr J M Clarke |
89,993 |
|
|
Mr M Dunoyer |
35,490 |
|
|
Mr D J Phelan |
44,997 |
|
|
Mr D Pulman |
29,153 |
|
* denotes an Executive Director
Grants made in 2006, to senior executives who have since been appointed Executive Directors or CET members were not subject to performance conditions. The Remuneration Committee therefore confirmed that the whole of the original grant was exercisable.
|
Number of options over Shares/ADSs exercisable |
||
|
Shares |
ADSs |
|
|
Dr M Slaoui* |
68,520 |
|
|
Mr S M Bicknell |
12,650 |
|
|
Mr E J Gray |
26,800 |
|
|
Mr D Learmouth |
12,650 |
|
|
Mr D S Redfern |
26,800 |
|
|
Ms C Thomas |
20,180 |
|
|
Mr J R Stephenne |
68,520 |
|
|
Mr W C Louv |
11,870 |
|
*denotes an Executive Director
The Company, Directors, and Persons Discharging Managerial Responsibility were advised of these transactions on 23 February 2009.
V A Whyte
Deputy Company Secretary
24 February 2009
|
Enquiries:
|
||
|
UK Media enquiries: |
Philip Thomson |
(020) 8047 5502 |
|
David Outhwaite |
(020) 8047 5502 |
|
|
Stephen Rea |
(020) 8047 5502 |
|
|
US Media enquiries: |
Nancy Pekarek |
(919) 483 2839 |
|
Mary Anne Rhyne |
(919) 483 2839 |
|
|
Kevin Colgan |
(919) 483 2839 |
|
|
Sarah Alspach |
(215) 751 7709 |
|
|
European Analyst/Investor enquiries: |
David Mawdsley |
(020) 8047 5564 |
|
Sally Ferguson |
(020) 8047 5543 |
|
|
Gary Davies |
(020) 8047 5503 |
|
|
US Analyst/ Investor enquiries: |
Tom Curry |
(215) 751 5419 |
|
Jen Hill |
(215) 751 7002 |
Related Shares:
Glaxosmithkline